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Abstract: Radiation therapy is a highly utilized therapy in the treatment of malignancies with
up to 60% of cancer patients receiving radiation therapy as a part of their treatment regimen.
Radiation therapy does, however, cause a wide range of adverse effects that can be severe and
cause permanent damage to the patient. In an attempt to minimize these effects, a small number of
compounds have been identified and are in use clinically for the prevention and treatment of radiation
associated toxicities. Furthermore, there are a number of emerging therapies being developed for use
as agents that protect against radiation-induced toxicities. The aim of this review was to evaluate and
summarise the evidence that exists for both the known radioprotectant agents and the agents that
show promise as future radioprotectant agents.
Keywords: radiotherapy; toxicity; oxidative stress; inflammation
1. Introduction
Radiation therapy is an important treatment modality for many malignancies with as many
as 60% of cancer patients receive ionizing radiation as a part of their therapeutic regimen [1].
While radiotherapy has variable success depending on the cancer being treated, the toxicity or side
effects associated with its use is of concern as it can affect quality of life [2]. Radiation toxicity can
manifest in a number of different ways as summarized in Table 1 [3–7]. Adverse effects from radiation
therapy are classified as early or late [3]. Early adverse effects occur during treatment or just after
its completion, and usually resolve within four to six weeks [3]. Late adverse effects are observed
several months to years after completion of treatment and may be permanent [3]. Another significant
concern is the potential for secondary malignancies to occur, which usually manifest 10 to 15 years
after treatment [8]. Therefore, there is considerable interest in agents that can serve as radioprotectants
to potentially protect patients during treatment and prevent the substantial effects of toxicity.
Direct and Indirect Mechanisms of Radiation-Induced Cell Damage
The nucleus is widely regarded as the principle target of ionizing radiation due to the fact that
it is the largest organelle in the cell [9]. The biological effects of radiation can be direct and indirect.
If energy from X- or γ-rays is absorbed in biological material, there is a possibility that it will interact
directly with critical targets in the cell. The atoms of the target itself may be ionised or excited, leading
to a chain of events culminating in biological damage. Alternatively, radiation may interact with
molecules in the cell to produce reactive species, capable of damaging critical targets. This is referred
to as an indirect action of radiation [9].
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Ionizing radiation is an effective DNA-damaging agent, producing a range of lesions in cellular
DNA, including more than 20 types of base damage, single-strand breaks, double-strand breaks,
and DNA crosslinks [10]. Exposure of cells to clinical doses of ionizing radiation typically causes:
1000 single-strand breaks, 40 double-strand breaks and 3000 damaged bases per Gray (Gy) [11].
DNA double strand breaks are regarded as the most important for cell death [10]. Although cells
have evolved complex repair mechanisms including homologous recombination and non-homologous
end-joining, many breaks are not repaired or are misrepaired, generally leading to cell death [10].
As cells pass through the cell cycle, they have to progress through mitosis when cell division occurs,
and cell death following irradiation occurs because of gross chromosomal changes leading to loss of
genetic material from cells when they attempt to divide. In general, there is a close association between
chromosomal fragments and cell killing by mitotic or reproductive death (failure to divide) [10].
However, cells respond to ionizing radiation-induce DNA damage by activating cell cycle checkpoints
in order to allow for DNA repair, and prevent transmission of damaged DNA to daughter cells [10].
Furthermore, oxidation of protein and lipids induced by the free radicals produced by exposure
radiotherapy is another major cause of healthy tissue damage [12,13].
In addition to direct ionisation of critical targets, ionizing radiation is able to induce cellular
damage indirectly via the production of reactive species. This indirect mechanism accounts for
approximately two thirds of the biological damage produced by X-rays, and is the central mechanism
of the ”oxygen fixation hypotheses” [14]. The ”oxygen fixation hypothesis” is widely believed to
account for the difference in radiation sensitivity between aerobic or normoxic and hypoxic cells [15].
Oxygen present at the time of irradiation, or within microseconds of the irradiation reacts chemically
with the DNA radical produced by ionizing radiation and ”fixes” (makes permanent) the damage [16].
In addition to free radical production, another mechanism of indirect toxicity post-irradiation
is through an inflammatory process [17]. Post-irradiation, there is initiation of a pro-inflammatory
reaction in the surrounding tissue resulting in the production of numerous pro-inflammatory cytokines
and chemokines shortly after irradiation [17]. These include interleukin-1, interleukin-6, tumour
necrosis factor α and transforming growth factor β [17]. TGF-β is of particular importance in
pathophysiology of radiation toxicity particularly with regard to mediating radiation-induced fibrosis
of the lungs and skin [18]. These mediators then initiate a long term inflammatory response and as
result chronic inflammation and tissue injury occurs as seen in Figure 1 [17].
Low doses of irradiation are known to induce TGF-β resulting in potential extensive lung and
skin damage [19]. This damage is mediated through changes to epithelial cell growth, a role of
TGF-β [17]. Furthermore, TNF-α, primarily produced by activated macrophages, has been shown to
play a crucial role in the acute phase of inflammation and has been shown to play a crucial role in
radiation-induced fibrosis [17]. Interleukin-1, a key pro-inflammatory cytokine, works in conjunction
with TNF-α to produce the skin reactions associated with radiation exposure [17]. Furthermore, given
the pro-inflammatory nature of interleukin-1, it plays a critical role in mediating the inflammatory
process post irradiation [17]. Inflammation post-radiation therapy is biphasic in response [20]. In the
first two weeks post-radiation exposure, cytokine production is induced then returns to normal by the
end of the two week mark [20]. The second increase in the cytokine expression occurs approximately
six to eight weeks post-radiation therapy [20]. This indicates that the pro-inflammatory response is
primarily responsible for the long-term toxicity associated with radiation toxicity, whereas the free
radical production is associated with the short-term toxicities.
In addition to local effects, systemic effects occur after exposure to irradiation [21]. These effects
include haematopoietic and immune cells resulting in decreases to the immune system [21].
Similar to local toxic effects of irradiation, systemic effects are mediated through oxidative stress,
damage to DNA and the production of pro-inflammatory cytokines [22]. Phenotypic changes to
macrophages occurs post irradiation, with cells changing from a predominantly anti-inflammatory
state to a pro-inflammatory state thereby releasing pro-inflammatory cytokines and chemokines [22].
Furthermore, activation of NLRP3 inflammasome, a key mediator in the innate immune response
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and proceeding inflammatory response, has been shown to be critical in the systemic response post
irradiation [22]. Other factors including the production of ATP, heat shock proteins and uric acid
have also been shown to play a role [22]. The combination of some or all of these factors results in
compromised cellular and tissue integrity ultimately leading to the deficits in immune system function
and the haematopoietic cellular effects [22]. Methods for addressing this will be outlined in further
detail below.
Table 1. List of adverse effects associated with radiation therapy and the associated cancers [3].
Adverse Effect Associated Cancer References
Depression Breast, lung, pancreatic, oropharyngeal, brain [3–5]
Fatigue Brain, head and neck, breast, lung, pelvic lymphatic system [3,5]
Dermatitis Head and neck, breast, prostate, perineal [3]
Cardiovascular disease Hodgkin lymphoma, breast, lung [3,6]
Pneumonitis Breast, lung, mediastinal [3]
Xerostomia Head and neck [3]
Mucositis and esophagitis Head and neck, thoracic [3]
Enteritis Abdominal, pelvic [3]
Proctitis Anal, rectal, cervical, uterine, prostate, bladder, testicular [3]
Emesis Upper abdominal, craniospinal, pelvic [3]
Cystitis Prostate, colorectal, bladder, pelvic [3,7]
Erectile dysfunction Prostate, colorectal [3]
Vaginal dryness and stenosis Cervical, endometrial, vaginal [3]
Infertility and teratogenicity Cervical, pelvic, testicular [3]
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Table 2. A summary of radioprotectant compounds.
Compound Mechanism of Action References
Clinically used radioprotectants
Amifostine Antioxidant [23–28]
Glutamine Antioxidant [29–35]
Pentoxifylline Antioxidant, anti-inflammatory [36–39]
Benzydamine Anti-inflammatory [40–42]
Sulfasalazine Anti-inflammatory, antioxidant [43,44]
Emerging Radioprotectants—Natural Products
Curcumin
(Curcuma longa) Antioxidant, anti-inflammatory, antiproliferatiive [45]
Quinic acid
(Coffee, cocoa) Antioxidant, decreases DNA damage [46]
lycopene
(Lycopersicon esculentum) Antioxidant, peroxidation inhibitor, free radical scavenger [47]
Rutin
(bioflavonoid) Antioxidant [48]
Hemocyanin
(Rapana thomasiana) Radiomitigator [49]
Black tea extract
(Camellia sinensis) Free radical scavenger [50]
Silymarin
(Silybum marianum) Anti-apoptotic agent, Reduces DNA damage [51]
Other Emerging Therapies
Vitamin D Protection of endothelial cells by modulating MAPK/SirT1 axis [52]
Melanin nanoparticles Protection of haematopoietic cells by preventing generation of free radicalsand of free radical scavenging [53]
Angiotensin-I-Converting
Enzyme (ACE) inhibitors
-Captopril
Haematopoietic radioprotection mediated by angiotensin II pathway
through AT1 receptors [54]
Palifermin Stimulation of cell proliferation and inhibition of cell apoptosis [55]
Manganese superoxide
dismutase-plasmid liposome
(MnSOD-PL) gene therapy
Antioxidant, decreases free radical production and inflammatory
cytokine release [56]
Genistein Antioxidant and anti-inflammatory [57]
Entolimod Apoptosis modulation [58]
PUMA inhibitors Apoptosis modulation [59]
Recilisib Intracellular signalling and DNA damage repair pathways P53down-regulation and up-regulation of AKT pathways [60,61]
γ-Tocotrienol Antioxidant, free-radical scavenger, HMG-CoA reductase inhibitor [62,63]
δ-Tocotrienol Antioxidant, enhance haematopoiesis, modulate signalling pathways [64,65]
3,31-Diindolylmethane Induces ATM-dependent DDR-like response, enhances radiation-inducedATM signalling and NF-κB activation [66]
Statins Anti-inflammatory [67–71]
Caffeine Antioxidant and anti-inflammatory [72–75]
Tetrahydrobiopterin Modulation of free radical-induced damage [76–81]
2.1. Clinically Used Radioprotectants
A number of clinically used radioprotectants have been identified and will be discussed below.
2.1.1. Antioxidants
Amifostine
Amifostine, a sulfhydryl-containing compound, has been shown to protect normal tissue during
radiation therapy [23]. It is thought to do this via the scavenging of free radicals produced after
exposure to radiation [23]. It is the most commonly used radioprotector clinically and is currently
the only approved therapy used in radiation toxicity [24]. Amifostine has been evaluated for its
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effects against a number of pathologies of radiation inducing lung disease, mucositis, xerastomia and
dysphagia [24].
To date, the most evidence lies with using amifostine preventatively for mucositis, xerastomia
and dysphagia [24]. A recent meta-analysis showed that pre-treatment and treatment with amifostine
both decreased the severity and the occurrence of all three of the manifestations associated with
radiation therapy by up to 60% [24]. Other studies have shown positive effects on mucositis with
the prophylactic use of amifostine [25], however, an earlier systematic review showed variability in
the nature of results and design of the original studies, and as a result no recommendations could be
made [26].
Another possible clinical use for amifostine in radiation-induced toxicity is for the associated lung
damage. Lung damage commonly manifests as pulmonary fibrosis or pneumonitis after exposure to
radiation therapy, especially in the upper regions of the body [82]. A number of in vivo studies have
shown amifostine, when given before irradiation, protected the lungs against radiation toxicity [27,28].
In these studies, amifostine was dosed at 200 mg/kg and administered intraperitoneally [27,28].
Amifostine has been shown to have no effect on protecting the tumour cells against radiation.
The accepted mechanism by which tumours remain sensitive to radiotherapy is due to the fact
that amifostine is a pro-drug that requires alkaline phosphatase for conversion to its active form [83].
Tumour cells only express low levels of alkaline phosphatase and therefore only low levels of amifostine
are converted to its active form [83].
Glutamine
Glutamine, a non-essential amino acid, has been widely studied for its potential beneficial effects
in a number of pathologies associated with radiation toxicity including mucositis, dermatitis and
oesphagitis [29–35]. Glutamines proposed mechanism of action in the prevention of radiation toxicity
is related to the formation of reduced glutathione (GSH) during its metabolism [84]. GSH is part of the
antioxidant defences and is well known for its protective effects against free radical damage [84].
A recent meta-analysis investigated the role of glutamine therapy in the prevention of mucositis
in radiation therapy [29]. It was shown that oral glutamine significantly decreased the incidence and
duration of mucositis and other associated effects including weight loss [29]. Dosing regimens of the
studies generally involved oral doses of 30 g/day that were administered in three divided doses [29].
Another common manifestation of radiation toxicity is dermatitis. Studies have shown glutamine
to be beneficial in the prevention of radiation–induced dermatitis [30]. A recent study has shown that
enteral glutamine not only reduced the severity of radiation-induced dermatitis but also significantly
decreased the numbers of patients presenting with the radiation-induced dermatitis [30].
A small study (n = 32) evaluated the protective benefits of glutamine therapy in the prevention
of oesphagitis associated with radiation therapy [31]. This study showed significantly less cases of
oesphagitis in the patients receiving glutamine in comparison to control [31]. This study supports the
findings of an earlier study showing that prophylactic dosing of glutamine at a dose of 10 g/8 h was
beneficial in the prevention of oesphagitis [32].
Glutamine has however to date, not shown any benefit in preventing the occurrence of
diarrhoea associated with radiation therapy [33]. This is further supported with a small randomized
controlled trial examining the effects of glutamine on the occurrence diarrhoea associated with chronic
enteritis [34]. This study showed no protective effect after glutamine was administered a dose of
30 g/day orally [34]. Another has shown glutamine to decrease the severity of diarrhoea associated
with radiation therapy [35].
2.1.2. Anti-Inflammatory Agents
Benzydamine
Benzydamine, a topical non-steroidal anti-inflammatory drug, has been evaluated for its use in
preventing and treating oral mucositis associated with radiation therapy [40,41]. It is proposed to
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do this via its anti-inflammatory effects and more specifically through its inhibition of TNF-α [85].
A recent study has shown the effectiveness of benzydamine mouth rinse in preventing chronic oral
mucositis [40]. This study showed that initiating benzydamine therapy one day prior to radiation
therapy and continuing for two weeks post-exposure, had no effect on the incidence or severity of
oral mucositis experienced by the patients at the Week 3 mark in comparison to placebo, however,
this trend changed at the Week 4 and 7 marks post-radiation therapy [40]. At these time points
benzydamine therapy decreased both the incidence and severity of oral mucositis in comparison
to placebo [40]. This further supports previous studies that have shown benzydamine, applied
topically, to be beneficial in decreasing the incidence and severity of oral mucositis associated with
radiation therapy [41]. Again another small study (n = 14) has shown the benefit of using benzydamine
mouthwash in oral mucositis after radiation therapy [42].
2.1.3. Mixed Acting Agents
Pentoxifylline
Pentoxifylline, a methyl xanthine derivative, has been shown to possess immunomodulating,
anti-inflammatory and vascular effects [36]. Pentoxifylline has been shown to be beneficial in
decreasing the risk of radiation toxicity in the lung after oral administration [36–39].
A small number of studies have been undertaken assessing the effects of pentoxifylline on
the pulmonary manifestations associated with radiation toxicity [36–39]. One study has shown
pentoxifylline to have no effect on acute lung injury following radiation therapy but have shown it
does however protect against chronic lung toxicity [37]. A number of other studies have, however,
shown pentoxifylline to have beneficial protective effects against radiation toxicity in both acute and
chronic toxicities [36,38]. These protective effects of pentoxifylline were observed when given orally at
a dose of 400 mg three times a day [36].
Pentoxifylline is thought to exert its protective effects against radiation-induced toxicity due
to its immunomodulating, anti-inflammatory and vascular effects [36]. In vivo studies suggest
that pentoxifylline decreases TNF-α mRNA and protein production at a dose of 100 mg/day [39].
This may be the mechanism by which pentoxifylline exerts its protective effects given that
TNF-α concentrations are increased at both a protein and transcriptional levels in the lungs [39].
Furthermore, prostaglandin E2, another marker of inflammation, is decreased in vivo when animals
are pre-treated with pentoxifylline prior to radiation exposure [86]. In addition to its anti-inflammatory
effects, pentoxifylline is proposed to protect against radiation-induced toxicities due to its antioxidant
effects [86]. Studies have identified that pentoxifylline increases GSH and decreases lipid peroxidation
in vivo post-radiation toxicity exposure [86]. This suggests that pentoxifylline has numerous
mechanisms of action in the prevention of radiation-induced toxicities.
2.1.4. Sulfasalazine
Sulfasalazine, a 5-aminosalicylate compound, has been evaluated for its effects in radiation
therapy-induced enteritis. A number of studies found sulfasalazine to be beneficial in preventing the
occurrence and reducing the severity of radiation-induced toxicity [43,44]. Sulfasalazine, administered
as 1 g twice a day starting on the day of radiation therapy, was shown at the end of five weeks
post-radiation exposure to significantly decrease acute gastrointestinal radiation toxicity as evidenced
through endoscopic evaluation [44]. A larger study (n = 87) assessing the effects of sulfasalazine (1 g
twice a day) found this therapy to be effective in decreasing the severity of diarrhoea associated with
radiation therapy [43]. Sulfasalazine’s proposed mechanism of action in the prevention and severity
reduction in radiation-induced toxicities is potentially two-fold. Not only is this an anti-inflammatory
agent but is also a free radical scavenger [87].
Antioxidants 2016, 5, 22 7 of 18
2.2. Emerging Radioprotectors
As described earlier, there are only a limited number of agents that are used to prevent and
manage the symptoms associated with radiation-induced toxicities, however, numerous agents have
shown potential and will be outlined below.
2.2.1. Natural Products as Radioprotective Agents
To date an abundance of natural products have been investigated as potential radioprotective
agents. Endogenous compounds such as cytokines, hormones, amino acids, carbohydrates and various
tissue extracts have been widely investigated [88–90]. Furthermore, numerous natural products have
been studied for their effectiveness towards radiation toxicity and will be outlined below.
2.2.2. Immunomodulators, Growth Factors and Cytokines
The emergence of recombinant technologies has enabled a large amount of research to be carried
out in the area of engineered human immunomodulators ultimately leading to new therapeutic
strategies. In the 1980s, it became apparent that endogenous compounds capable of non-specifically
enhancing immunologic and haematopoietic responses could be utilised as radioprotectors [88,91].
The attention fell to cytokines and growth factors as new agents of radioprotection against radiation
syndrome, and to date much work has been carried out to this end. Singh et al. noted studies have
shown that although various cytokines have the ability to aid bone marrow restoration after treatment
with cytotoxic drugs and exposure to radiation, not all possess the ability to be therapeutic after their
complex interaction within the cytokine pathways they’re involved in are understood [88,89].
Presently, IL-1, TNF-α, SCF (mast cell growth factor), IL-12, the endogenous steroid family
of 5-androstene and recombinant peptides derived from flagellin (CBLB502) and mycoplasma
(CBLB601, CBLB6012 and CBLB6013) appear to significantly protect animals to varying degrees
when administered prior to lethal doses of radiation [88,89]. A number of publications by Neta et al.
studying the use of cytokines as radioprotectors has found the immunomodulator IL-1 produced
a radioprotective effect when administered to mice prior (20 h) to whole body irradiation [91,92].
The protection was seen to be time and dose dependant in relation to irradiation, as noted,
administration of IL-1 shortly after exposure to radiation did not have the same outcome with limited
ability to save mice exposed from death. Furthermore, Neta et al. has hypothesised that the need for a
lag phase between IL-1 administration and irradiation suggests that the radioprotection obtained from
IL-1 is mediated by other agents induced by IL-1 therefore not by IL-1 itself directly [91]. This study
presents evidence that conflicts the findings of the causes of radiation toxicity. As highlighted earlier,
IL-1 and TNF-α have both been shown to play a crucial role in the inflammatory process post irradiation
suggesting that further studies are required investigating these effects [17].
SCF has been shown to synergise in radioprotection with IL-1 as the release of IL-1 increases the
amount of bone marrow cells expressing the endogenous receptor c-kit, which SCF is a natural
ligand and thereby acts on [89]. However, the exact role that SCF plays in radioprotection is
ambiguous currently, as numerous papers report conflicting experimental outcomes when SCF is
used in combination with other cytokines and growth factors, which certainly further highlights the
complex interplay between these endogenous compounds [89].
Several other cytokines and growth factors, including G-CSF, GM-CSF and erythropoietin (EPO),
have been investigated as radioprotective agents. These agents act by stimulating the stem progenitor
cells, promoting haematopoietic marrow repopulation [89,93]. However, these agents have been shown
to be of limited use in radiotherapy [89], primarily due to pro-inflammatory and immunogenicity
adverse effects, which in many cases (EPO) were seen to be severe [94].
Numerous other growth factors have been evaluated for their radiomodulating effects and
furthermore drugs have been utilised that target these growth factors proving to have a further role
in radioprotection. Anti-VEGF therapy using bevacizumab has been shown to decrease the extent of
radiation necrosis in a small clinical trial of patients undergoing radiotherapy for brain tumours [95].
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2.2.3. Phyto-Radioprotectors
Phytochemicals produce their radioprotective effects through various mechanisms, with their
activity being measured predominately as either antioxidants, free radical scavengers, DNA repair
modulators or preventers of DNA damage and lastly based on anti-inflammatory action [96]. In the
past 20 years, there has been a major shift towards evaluating phytochemicals as radioprotectors,
primarily due to their potential bioequivalence, efficacy and in most cases low toxicity, relative to many
of the established synthetic compounds available [97].
Plants are naturally instilled with radiation protective mechanisms as they rely on the harsh
sunlight based radiation in order to grow. This innate radioprotective ability is in part due to
the numerous antioxidant phytochemicals that they possess as part of normal metabolic processes.
Polyphenols like flavonoids and their naturally occurring derivatives are structurally adapted in order
to be activated by electron donating substituents which inhibit energy transfer mechanisms, ultimately
suppressing oxidative stress and stabilising redox processing cells [98,99].
As can be seen in Table 2, antioxidant activity appears to be almost an essential characteristic
of phytochemicals intended for radioprotection outcomes. Hence, the polyphenols make up the
majority of compounds tested. These include all flavonoid based compounds, of which there are
over 5000 recognised and their number is constantly increasing [90]. The use of polyphenols and the
antioxidant lycopene are described in further detail below.
2.2.4. Polyphenols as Radioprotectant Agents
Numerous polyphenols have been shown to have protective effects against radiation toxicities.
Amongst these include curcumin, caffeic acid and ferulic acid which will be discussed in further detail
below. These compounds have been shown to possess anti-inflammatory and antioxidant properties
that are likely to target the indirect pathway of radiation toxicity [12,75,100–108].
Numerous studies have evaluated the radioprotective effects of curcumin both in vitro and in vivo.
In vivo studies have shown curcumin to have protective effects against both acute and chronic skin
toxicities when administered before or after exposure to radiation [100,101]. Furthermore, pre- or
post-treatment with curcumin afforded a significantly decreased expression of pro-inflammatory
cytokines and chemokines including IL-1, IL-6, TNF-α and TGF-β [100,101]. In vitro studies have
shown similar results to in vivo studies. Curcumin has been shown to decrease lipid peroxidation
and increase antioxidant effects in lymphocytes [102]. A limited number of human studies have
evaluated the effectiveness of curcumin on reducing radiation-induced toxicity. One study has
shown that oral administration of curcumin during radiotherapy afforded some protection against
the severity of radiation-induced dermatitis in breast cancer patients [103]. A small randomised
controlled trial (n = 40) showed curcumin to afford protection against urinary symptoms in patients
receiving irradiation for prostate cancer [109]. It did not however provide any protection against
bowel symptoms when dosed at 3 g/day [109]. Furthermore, a second randomised controlled trial
found that 6 g/day of curcumin decreased radiation-induced dermatitis associated with breast cancer
treatment [103].
Caffeic acid and caffeic acid phenethyl ester have shown promise in in vitro and in vivo studies
assessing their protective effects in radiation-induced toxicity. In vivo studies have shown caffeic
acid phenethyl ester to decrease lipid peroxidation and increase antioxidant defences in the heart
and lung tissue of irradiated mice [104,105]. Furthermore, in vitro studies have shown caffeic acid to
protect against radiation-induced DNA damage and lipid peroxidation in human peripheral blood
lymphocytes [106].
Ferulic acid has been shown to possess anti-inflammatory and antioxidant activity indicating
that its protective effects towards radiation toxicity are through targeting the indirect pathway of
radiation toxicity [75]. In vitro studies have shown ferulic acid to protect against radiation toxicity
predominantly via its antioxidant effects [12]. Pre-treatment of hepatocytes and lymphocytes with
ferulic acid (1, 5 and 10 µg/mL) was shown to significantly decrease lipid peroxidation and damage
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to DNA after exposure to γ-irradiation [12,107]. Furthermore, it resulted in significant increases in
antioxidant defences such as antioxidant enzymes and reduced glutathione (GSH) in comparison
to the control group [12,107]. In vivo studies have also shown ferulic acid to be protective against
γ-radiation toxicities [108]. Pre-treatment of mice with ferulic acid (50 mg/kg) 1 h prior to exposure to
γ-radiation resulted in decreased DNA strand breaks in comparison to control [108].
The evidence provided suggests that polyphenols and their derivatives may provide significant
improvement in radiation-induced toxicities, however, given the limited evidence in human
randomized controlled trials, further studies are warranted before they are recommended for
clinical use.
2.2.5. Lycopene as a Radioprotectant Agent
Lycopene, a carotenoid, has been studied for its effects on a number of radiation-induced toxicity in
both in vivo and in vitro models of radiation exposure. In vivo studies have shown lycopene to protect
against radiation toxicity predominantly through an antioxidant pathway [110–114]. Treatment of rats
with lycopene affords protection against increases in markers of lipid peroxidation and decreases in
antioxidant defences in hepatic and small intestine tissue [110–112]. Similarly, lycopene was found
to possess the same properties in an in vitro model of radiation toxicity in hepatic and lymphocytic
cells [113,114].
2.2.6. Other Emerging Radioprotectant Therapies
Antioxidants
Endothelial cells (EC) are the most sensitive cells located in the vascular wall to radiation-induced
ROS. Recent studies with human umbilical vein endothelial cells (HUVECs) demonstrate Vitamin D
(Vit. D) protects endothelial cells from oxidative stress through modulating the mitogen-activated
protein kinase (MAPK) signalling and the phospho-38 inactivation. Inactivation of p38 MAPK is an
important mechanism by which potential radioprotective agents may exert their effects. Studies have
shown that in oxygen-dependent irradiation, downstream activation of p38 MAPK is critical for
damage to occur [115]. Furthermore, increases in oxidative stress results in mitochondrial permeability
transition which leads to the activation of MAPK pathways post-irradiation [116]. This suggests a
number of possible mechanisms by which Vit. D may exert its protective effects. Modulation of
anti-apoptotic and anti-senescence MAPKs inhibits proteasome-mediated SirT1 protein degradation
and resultant up-regulation of SirT1 protects EC from oxidant injury [52]. In addition, it has
been observed that Vit. D deficiency is relatively common among patients with cancer [117] and
phase III trials are currently evaluating radioprotective effect of Vit. D supplements [118]. It is
important to note that many of the signal transduction pathways in the MAPK superfamily are
involved in radiation-induced toxicity [119]. Furthermore, their role in inducing or protecting against
radiation-induced toxicity is highly variable and is dependent on numerous factors including the cell
type and the duration of exposure to radiation [119].
Melanin, a high-molecular weight natural pigment prevents formation of free radicals and
scavenging of the highly destructive radicals generated by the radiolysis of water [120]. A recent study
involving intravenous administration of melanin-coated nanospheres demonstrates protection of bone
marrow against radiotoxicity during radioimmunotherapy of cancer [53]. Angiotensin I-Converting
Enzyme Inhibitors (ACEIs) such as perindopril and captopril induces radioprotection by preserving
murine haematopoietic short-term reconstituting cells in vivo [121]. Several mechanisms are involved
in ACEIs’ haematopoiesis action. Primarily, ACEIs inhibit angiotensin II formation and increase plasma
concentration of AcSDKP (acetyl-N-Ser-Asp-Lys-Pro), an ACE substrate and a negative regulator of
haematopoiesis [122]. A recent clinical study demonstrated ACEIs significantly reduced the incidence,
severity and duration of radiation-induced proctitis [54].
γ-Tocotrienol (GT3), a strong antioxidant [62], significantly protected haematopoietic tissue
by preserving haematopoietic stem cells and progenitor cells and by preventing persistent DNA
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damage [123]. Further preclinical studies demonstrated GT3 conferred protection of intestinal cells
from a GI-toxicity dose of radiation through upregulation of antiapoptotic and downregulation of
proapoptotic factors, both at the transcriptional and the protein levels [60].
The modulation of the tetrahydrobiopterin pathway is gaining popularity in the potential
treatment and prevention of radiation toxicity. Tetrahydrobiopterin is a cellular non-enzymatic
redox sensitive antioxidant that is a co-factor in a number of biochemical pathways including
aromatic amino acid hydroxylases and nitric oxide synthases [76]. Nitric oxide synthase, when
exposed to increased conditions of oxidative stress, switches from producing nitric oxide to
producing a number of free radicals including superoxide and peroxynitrite [77]. It is thought that
inadequate supply of tetrahydrobiopterin is critical role in the switch to increased production of
free radicals [77]. Furthermore, tetrahydrobiopterin has been shown to possess reactive oxygen
species-scavenging activity suggesting that a deficit could contribute to radiation toxicity through a
number of pathways [77,78]. Studies have shown that free radicals can decrease the concentrations of
tetrahydrobiopterin [79]. This is thought to occur through dysregulation of the enzyme responsible
for the homeostasis of tetrahydrobiopterin production, GTP cyclohydrolase I feedback regulatory
protein (GFRP) [79–81]. This suggests that tetrahydrobiopterin or compounds that modulate the
tetrahydrobiopterin pathway may be beneficial as a measure to prevent and/or treat radiation toxicity.
Emerging Anti-Inflammatory Agents
Entolimod, a toll-like receptor 5 (TLR5) ligand activates NF-κB signalling which inhibits
apoptosis by suppression of p53 and upregulation of antiapoptotic cytokines [124]. This modulation
of apoptosis is thought to play an important role in entolimod’s radioprotective activity [125].
In recent preclinical studies, entolimod demonstrated radioprotective activity in rodents and in
non-human primates (rhesus macaques). A single dose intramuscular injection of entolimod enhanced
morphological recovery of haematopoietic and immune system organs, decreased severity and
duration of thrombocytopenia, anemia and neutropenia, and increased clonogenic potential of the
bone marrow. Overall, entolimod reduced apoptosis and accelerated crypt regeneration in the
gastrointestinal tract [58]. Entolimod is currently in clinical development as a medical radiation
countermeasures (MRC) to reduce the lethality of high-dose total body ionizing irradiation.
Statins, or HMG-CoA reductase inhibitors, are another class of emerging therapies to
treat radiation toxicities [67–71]. Again, statins predominantly exert their activities towards
modulating the indirect pathway associated with radiation toxicity. In vivo studies have shown that
lovastatin inhibited radiation-induced increases in pro-inflammatory mediators in lung tissue [67,68].
Furthermore, simvastatin and pravastatin administration was associated with protection of the
gastrointestinal tract in vivo [69,70]. Similar results were observed in in vitro studies with pravastatin
decreasing a number of pro-inflammatory cytokines including IL-6 and IL-8 in lung endothelial cells
exposed to radiation [71].
Mixed Acting Agents
Palifermin, an N-truncated recombinant human keratinocyte growth factor (KGF) protects the
mucosal epithelium and promotes its early regeneration. Its protective actions appear to be due to
multiple biological activities, which include inhibition of epithelial cell apoptosis and DNA damage,
up-regulation of detoxifying enzymes and down-regulation of pro-inflammatory cytokines along
with enhanced migration, proliferation and differentiation of epithelial cells [126]. Recent preliminary
study confirmed clinical effectiveness of palifermin in prevention and treatment of oral mucositis
in patients undergoing allogeneic stem-cell transplantation for the treatment of acute lymphoblastic
leukaemia [55].
A superoxide dismutase transgene protects normal cells against radiation-induced cellular
damage [127]. Manganese superoxide dismutase (MnSOD) transgene overexpression elevates
antioxidant stores in tissues including levels of glutathione and decreases inflammatory cytokine
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production (IL-1, TNF-α and TGF-β) [128]. Preclinical investigation using intravenous manganese
superoxide dismutase-plasmid liposomes (MnSOD-PL) administration demonstrated significant
protective effect against ionizing radiation [56].
Genistein, a soy isoflavone protects cells against radiation-induced injury. The protective effect
of genistein conferred through combination of cellular activities, including antioxidant activity, free
radical scavenging activity and anti-inflammatory activity [129]. Preclinical studies demonstrated
genistein protected haematopoietic progenitor cell recovery and survival [130]. In addition, recent
clinical evidence indicates that genistein in conjugation with radiation therapy reduced the urinary,
intestinal, and sexual adverse effects in patients with prostate cancer [57].
Another methyl xanthine derivative, caffeine, has been shown to have potential protective
effects against radiation toxicity [72–74]. A cohort study in patients receiving radiation therapy
for cervical cancer found an inverse correlation between the level of caffeine consumption at the time
of the radiation therapy and the incidence of severe late radiation toxicity [73]. In vivo studies have
evaluated the effectiveness of caffeine dosing on the survival of mice after exposure to lethal doses of
γ-irradiation [72]. Caffeine afforded no protective benefits when dosed at the same time as irradiation;
however, when dosed at high concentrations (80 mg/kg or 100 mg/kg) 30 or 60 min prior to irradiation,
50% and up to 70% survival at 25 days was observed, respectively [72]. Furthermore, caffeine
was shown to decreased the severity of radiation-induced skin toxicities associated with radiation
therapy [74]. Caffeine has been shown to possess anti-inflammatory and antioxidant properties [75].
These effects may contribute to the protective effects of caffeine in radiation-induced toxicity.
Other Agents
PUMA, p53-Upregulated Mediator of Apoptosis plays an essential role in p53-dependent and
DNA damage-induced apoptosis. On activation of PUMA by a wide range of apoptotic stimuli, PUMA
directly binds to anti-apoptotic Bcl-2 like protein and initiates intrinsic apoptosis pathways [131].
Considering the importance of the interactions of PUMA/Bcl-2 like sproteins in initiating apoptosis,
small molecules that disrupt or prevent these key interactions and consequently suppress PUMA
induced apoptotic response have been investigated. In vitro analysis demonstrated several lead
compounds conferred considerable protection against PUMA-dependent and radiation-induced
apoptosis. Further work and optimization of the lead structures identified in this work required to
develop PUMA inhibitors as safe and effective approach to protect radiation-induced tissue injury [59].
Recilisib, a chlorobenzyl sulfone derivative, is in clinical development as radiation
countermeasure. Recent preclinical study indicates, recilisib administration after exposure to ionizing
radiation enhances the recovery of haematopoietic cells by attenuating DNA damage response [60].
In addition, in vitro and in vivo studies on mouse and human bone marrow cell demonstrated recilisib
effectively protects cells from radiation-induced damage. Further mechanistic studies showed recilisib
confers its protective effect through the up-regulation of Pl3-Kinase/AKT pathways in cells exposed to
radiation [61].
In recent preclinical study, apart from a potent antioxidant activity, the Vitamin E isoform
δ-Tocotrienol (DT3) demonstrated radioprotection by enhancing haematopoiesis and modulating
signalling pathways. Further investigation of radioprotection mechanism indicates DT3 reduced
activation of caspases (caspases 3, 7 and 8) inherent to apoptosis, while increasing autophagy-related
to beclin-1 expression in irradiated bone marrow [65]. DT3 significantly increased haematopoietic
progenitor cell survival and regeneration of haematopoietic microfoci and progenitor cells in irradiated
mouse bone marrow. In addition, DT3 also protected human CD34+ cells from radiation-induced
damage through activation of extracellular signal-related kinase 1/2 (Erk1/2) phosphorylation and
significant inhibition of formation of DNA-damage marker γH2AX foci [64].
Recent evidence indicates that DIM (3,31-Diindolylmethane) protected cultured cells against
ionizing radiation by a unique mechanism: DMI activated an Ataxia telangiectasia mutated
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(ATM)-driven DNA damage (DDR)-like response without causing DNA damage and induced NF-kB
signalling [132].
Collectively, these novel approaches will hopefully lead to development of safe and effective
radioprotective agent [83,133,134].
3. Conclusions
In conclusion, radiation toxicity is a major problem for patients receiving therapy for malignancies.
To date, there are only a limited number of radioprotectant agents used clinically to minimise
the severity and duration of toxicities associated with radiation therapy. There are a number of
promising agents emerging, however, further studies assessing their effects is required. This review
has highlighted that there is a lack of high quality human studies for many of the agents described
above. In particular, further studies in humans are required to evaluate the safety and efficacy of these
emerging therapies in not only the prevention and treatment of radiation toxicity but also their effects
on tumour sensitivity.
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